Metrics as of 10/15/2026, 08:29 AM (Berlin time), refresh in progress.
BriaCell Therapeutics Stock
BriaCell Therapeutics Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- William V. Williams
- Employees
- 17
- Market cap
- $46 M
- IPO
- 13/08/2012
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in…
BriaCell Therapeutics stock: price history
1D
-1.1%
1W
-7.7%
1M
+5.4%
6M
-17.1%
YTD
-46.4%
1Y
-67.0%
2Y
-97.4%
5Y
-99.7%
10Y
-99.9%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~2% stronger price swings than usual
Ask the agents about BriaCell Therapeutics
Analyst assessment of BriaCell Therapeutics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 27/08/2025
BriaCell Therapeutics stock metrics
P/E
-0.3
P/B
1.11
EV/EBITDA
-0.8
RETURN ON EQUITY
-29.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/04/2026
Free float & liquidity
FREE FLOAT
90.3%
FLOAT SHARES
7,859,562
AVG. DAILY VOLUME (30D)
7,687
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BriaCell Therapeutics stock
What does BriaCell Therapeutics do?
BriaCell Therapeutics Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is William V. Williams, the company employs around 17 people.
The IPO was on 13/08/2012; the stock trades on TSX under the ticker BCT.TO.
What do analysts say about BriaCell Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 27/08/2025).
This is an external assessment, not a statement by Market Jury.
When does BriaCell Therapeutics report next?
Around past earnings, price swings were roughly 2% stronger than usual.
Does BriaCell Therapeutics pay a dividend?
No, BriaCell Therapeutics currently does not pay a dividend.
Which stocks are comparable to BriaCell Therapeutics?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get BriaCell Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess BriaCell Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.